MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy
A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of MEDOTIXN® in Subject With Benign Masseteric Hypertrophy
Sponsor: Medy-Tox
Listed as NCT03452345, this PHASE3 trial focuses on Masseter Muscle Hypertrophy and remains completed. Sponsored by Medy-Tox, it has been updated 7 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Recruiting → Completed
▶ Show 2 earlier versions
-
Apr 2019 — Aug 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — Apr 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Medy-Tox
For direct contact, visit the study record on ClinicalTrials.gov .